Journal
FEBS OPEN BIO
Volume 4, Issue -, Pages 735-740Publisher
WILEY
DOI: 10.1016/j.fob.2014.08.001
Keywords
Antimycobacterial peptides; ESAT6; Mycobacterium tuberculosis; Protein-protein interaction
Categories
Funding
- ICGEB internals grants
Ask authors/readers for more resources
Tuberculosis (TB) is a huge global burden, with new and resistant strains emerging at an alarming rate, necessitating an urgent need for a new class of drug candidates. Here, we report that SL3, a novel 33-amino acid peptide, causes debilitating effects on mycobacterial morphology. Treatment with SL3 drastically inhibits the growth of Mycobacterium tuberculosis in vitro as well as in a pre-clinical mouse model for M.tb infection. Microarray analysis of SL3-expressing strain demonstrates wide-scale transcriptional disruption in M.tb. We therefore believe that SL3 and similar peptides may herald a new approach towards discovering new molecules for TB therapy. (C) 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available